Syneos Health, Inc. (SYNH)

Syneos Health, Inc. (SYNH) Healthcare & Pipeline Overview

Syneos Health, Inc. (SYNH) is a global biopharmaceutical outsourcing company, providing clinical and commercial solutions. With a focus on Phase I-IV clinical development and commercialization services, Syneos Health supports pharmaceutical, biotechnology, and healthcare industries across North America, Europe, and Asia-Pacific, leveraging its integrated solutions and expertise.

What Is the Investment Thesis for SYNH?

Syneos Health, Inc. presents a compelling investment case based on its integrated clinical and commercial solutions within the growing biopharmaceutical outsourcing market. With a market capitalization of $4.46B and a P/E ratio of 16.61, the company demonstrates a solid financial foundation. A key value driver is the increasing demand for outsourced clinical trial services, driven by the rising complexity and costs of drug development. Syneos Health's comprehensive service offerings, spanning from Phase I to IV clinical trials to commercialization, position it to capture a significant share of this market. The company's global presence allows it to serve a diverse client base and capitalize on growth opportunities in emerging markets. However, potential risks include intense competition and regulatory changes that could impact the drug development process. The company's beta of 1.58 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

SYNH Key Highlights

• Market Cap of $4.46B reflects substantial investor confidence in Syneos Health's market position.
• P/E ratio of 16.61 indicates a reasonable valuation compared to its earnings.
• Profit Margin of 4.9% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 23.3% shows the efficiency of Syneos Health's service delivery.
• Beta of 1.58 suggests higher volatility compared to the market, potentially offering higher returns but also increased risk.

Who Are SYNH's Competitors?

SYNH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYNH's Key Strengths?

• Integrated clinical and commercial solutions.
• Global presence and reach.
• Experienced management team.
• Strong reputation in the biopharmaceutical industry.

What Are SYNH's Weaknesses?

• Dependence on the biopharmaceutical industry.
• Exposure to regulatory changes.
• Competition from other CROs and commercialization service providers.
• Profit margin could be higher.

What Could Drive SYNH Stock Higher?

• Increasing demand for outsourced clinical trial services due to rising R&D spending.
• Expansion of Syneos Health's service offerings and geographic reach.
• Potential acquisitions of complementary businesses to enhance capabilities.
• Adoption of digital technologies to improve efficiency and reduce costs.
• Growth in emerging markets, particularly in Asia-Pacific and Latin America.

What Are the Key Risks for SYNH?

• Financial-distress signal — its Altman Z-Score of 1.42 sits in the distress zone (elevated bankruptcy risk).
• Insider selling — insiders were net sellers of roughly $2.7M recently.
• Economic downturns affecting R&D spending by pharmaceutical companies.
• Intense competition from other CROs and commercialization service providers.
• Regulatory changes impacting drug development and commercialization processes.
• Patent expirations and generic drug competition affecting demand for new drug development.
• Dependence on key clients and contracts.

What Are the Growth Opportunities for SYNH?

• Expansion in Emerging Markets: Syneos Health can capitalize on the growing pharmaceutical markets in Asia-Pacific and Latin America. These regions are experiencing increased healthcare spending and a rising demand for clinical trial services. By establishing a stronger presence and tailoring its services to local needs, Syneos Health can tap into new revenue streams. The market size for clinical trials in emerging markets is projected to reach billions by 2028, offering a significant growth opportunity.
• Strategic Partnerships and Acquisitions: Syneos Health can pursue strategic partnerships and acquisitions to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities, such as specialized CROs or technology providers, can enhance its competitive position and attract new clients. This strategy can accelerate growth and create synergies within the organization. The timeline for potential acquisitions is ongoing, with the company continuously evaluating opportunities.
• Adoption of Digital Technologies: Syneos Health can leverage digital technologies, such as AI and machine learning, to improve the efficiency and effectiveness of its clinical trial services. These technologies can automate tasks, reduce costs, and accelerate the drug development process. By investing in digital innovation, Syneos Health can differentiate itself from competitors and attract clients seeking cutting-edge solutions. The implementation of digital technologies is an ongoing process.
• Focus on Personalized Medicine: Syneos Health can focus on providing services for the development of personalized medicine therapies. This rapidly growing field requires specialized expertise in areas such as genomics and biomarker analysis. By building capabilities in personalized medicine, Syneos Health can tap into a high-growth market segment and attract clients developing innovative therapies. The market for personalized medicine is projected to reach billions by 2027.
• Enhancing Commercial Solutions: Syneos Health can further develop its commercial solutions segment to provide integrated services throughout the entire drug lifecycle. This includes expanding its capabilities in areas such as market access, pricing, and reimbursement. By offering a comprehensive suite of commercial services, Syneos Health can strengthen its relationships with clients and generate recurring revenue streams. The expansion of commercial solutions is an ongoing strategic priority.

What Opportunities Does SYNH Have?

• Expansion in emerging markets.
• Strategic partnerships and acquisitions.
• Adoption of digital technologies.
• Focus on personalized medicine.

What Threats Does SYNH Face?

• Economic downturns affecting R&D spending.
• Increased competition in the CRO market.
• Regulatory changes impacting drug development.
• Patent expirations and generic drug competition.

What Are SYNH's Competitive Advantages?

• Integrated Solutions: Offers both clinical and commercial solutions, creating a comprehensive service offering.
• Global Reach: Operates in multiple regions, providing access to diverse patient populations and markets.
• Expertise: Employs a team of experienced professionals with deep knowledge of the biopharmaceutical industry.
• Reputation: Has a strong track record of successful clinical trials and commercialization projects.

What Does SYNH Do?

Syneos Health, Inc., established in 2010 and headquartered in Morrisville, North Carolina, is a prominent biopharmaceutical outsourcing solutions company. Formerly known as INC Research Holdings, Inc. until its rebranding in January 2018, Syneos Health operates across North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company is structured into two primary segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment focuses on providing services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. These services encompass product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affairs services. The Commercial Solutions segment offers commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communication services), and consulting services to the pharmaceutical, biotechnology, and healthcare sectors. Syneos Health's integrated approach aims to accelerate drug development and commercialization processes for its clients, positioning it as a key partner in the biopharmaceutical industry.

What Products and Services Does SYNH Offer?

• Provides clinical development services for drugs, biologics, and devices.
• Offers commercialization solutions to pharmaceutical and biotechnology companies.
• Manages Phase I to IV clinical trials.
• Provides regulatory consulting and support.
• Offers technology-enabled patient recruitment and engagement.
• Provides public relations, advertising, and medical communication services.
• Offers consulting services to the healthcare industry.

How Does SYNH Make Money?

• Generates revenue through fees for clinical development services.
• Earns revenue from commercialization services, including deployment and communication solutions.
• Provides consulting services on a project basis.
• Contracts with pharmaceutical and biotechnology companies to manage clinical trials.

What Industry Does SYNH Operate In?

Syneos Health operates within the medical diagnostics and research industry, a segment experiencing growth due to increasing R&D spending by pharmaceutical and biotechnology companies. The global market for clinical trial services is projected to reach billions by 2026, driven by the rising complexity of drug development and the need for specialized expertise. Syneos Health competes with other contract research organizations (CROs) and commercialization service providers. Key competitors include companies like AMED and LHCG, which offer similar services. The industry is also influenced by regulatory changes and technological advancements, requiring companies to adapt and innovate to maintain a competitive edge.

Who Are SYNH's Key Customers?

• Pharmaceutical companies developing new drugs.
• Biotechnology companies researching and developing biologics.
• Healthcare companies seeking commercialization support.
• Medical device companies conducting clinical trials.

Net sellingInsider Activity

The most recent 12 insider filings for Syneos Health, Inc. break down as 12 sales and 0 purchases. On net that is roughly 94K shares disposed (about $2.7M), a signal worth weighing alongside the fundamentals.

F-Score 7/9Financial Health

Syneos Health, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.42 places it in the distress zone, a signal of elevated financial risk.

ROE 8%Key Financial Metrics

Return on equity for Syneos Health, Inc. stands at 7.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.3%, showing how much profit it generates from its asset base. SYNH trades at a trailing price-to-earnings ratio of 16.61, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.0%, the inverse of the P/E and a quick read on earnings relative to price.

Syneos Health, Inc. (SYNH) Valuation Context

Valued at $4.46B, SYNH is classified as a mid-cap stock.

Company Profile

Syneos Health, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Morrisville, US. The company is led by CEO Michelle Keefe. SYNH has traded publicly since 2014.

SYNH Financials

SYNH Latest News

SYNH Analyst Consensus

SYNH MoonshotScore

SYNH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources